Vivo Opportunity, Llc Acquires 600,000 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERNGet Rating) major shareholder Vivo Opportunity, Llc purchased 600,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 7th. The stock was acquired at an average cost of $3.60 per share, for a total transaction of $2,160,000.00. Following the transaction, the insider now owns 3,581,592 shares in the company, valued at approximately $12,893,731.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Vivo Opportunity, Llc also recently made the following trade(s):

  • On Monday, August 15th, Vivo Opportunity, Llc purchased 1,218 shares of Terns Pharmaceuticals stock. The stock was acquired at an average cost of $2.99 per share, for a total transaction of $3,641.82.
  • On Friday, August 12th, Vivo Opportunity, Llc acquired 1,123,021 shares of Terns Pharmaceuticals stock. The stock was purchased at an average price of $2.98 per share, with a total value of $3,346,602.58.

Terns Pharmaceuticals Stock Performance

NASDAQ:TERN opened at $5.27 on Friday. The firm has a market cap of $133.65 million, a price-to-earnings ratio of -2.47 and a beta of -0.33. Terns Pharmaceuticals, Inc. has a 52 week low of $1.45 and a 52 week high of $11.98. The firm has a 50-day moving average price of $3.12 and a two-hundred day moving average price of $2.61.

Terns Pharmaceuticals (NASDAQ:TERNGet Rating) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.08. As a group, sell-side analysts forecast that Terns Pharmaceuticals, Inc. will post -2.18 earnings per share for the current year.

Institutional Investors Weigh In On Terns Pharmaceuticals

Several large investors have recently modified their holdings of TERN. Decheng Capital Management III Cayman LLC purchased a new stake in shares of Terns Pharmaceuticals during the 1st quarter worth approximately $2,121,000. Ikarian Capital LLC purchased a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $1,736,000. Affinity Asset Advisors LLC purchased a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $995,000. Point72 Asset Management L.P. increased its stake in shares of Terns Pharmaceuticals by 307.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 500,000 shares of the company’s stock worth $1,240,000 after purchasing an additional 377,427 shares during the last quarter. Finally, Millennium Management LLC grew its stake in Terns Pharmaceuticals by 213.7% in the 2nd quarter. Millennium Management LLC now owns 277,688 shares of the company’s stock valued at $689,000 after buying an additional 189,178 shares in the last quarter. Hedge funds and other institutional investors own 92.50% of the company’s stock.

Terns Pharmaceuticals Company Profile

(Get Rating)

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH.

Featured Articles

Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.